Pyxis Oncology, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Pyxis Oncology, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.86M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $16.15M | Mar 23, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($79.62M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($77.33M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($73.79M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($120.72M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($75.98M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($12.83M) | Mar 29, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($84.42M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($89.46M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($82.20M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($123.48M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($69.72M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($12.89M) | Mar 29, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.70M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $58.75M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $49.59M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $86.13M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $51.05M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $9.05M | Mar 29, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($63.50M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($57.67M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($70.71M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($89.34M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($35.33M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($10.08M) | Mar 29, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.0K | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $237.0K | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $6.73M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $6.40M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $540.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.48M | Mar 29, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.52M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $157.18M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $173.73M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $211.38M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $280.02M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $10.15M | Mar 29, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.11M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $36.43M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $48.02M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $50.56M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $18.71M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $3.85M | Mar 29, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.41M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $120.75M | Mar 23, 2026 |
| FY2025 | Dec 31, 2023 | $125.70M | Mar 23, 2026 |
| FY2024 | Dec 31, 2022 | $160.82M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $261.31M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | ($15.65M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | ($2.87M) | Mar 29, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($443.18M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($363.56M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($286.23M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($212.44M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($91.72M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($15.74M) | Mar 29, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.42M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $19.47M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $9.66M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $179.29M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $274.74M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $8.08M | Mar 29, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (8) | Mar 22, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (8) | Mar 22, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 62.69M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 59.97M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 44.75M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 34.96M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 32.22M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 1.29M | Mar 29, 2022 |